Drug targeting strategies for photodynamic therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 500-525

  Schmitt, Frédéric ^a   Juillerat Jeanneret, Lucienne ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug Targeting; Nanoparticles; Organometallics; Peptides; Photodynamic Therapy; Proteins

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; CATIONIC PEPTIDE; CETUXIMAB; CIRCULATING PROTEIN; CISPLATIN; ESTROGEN RECEPTOR; FOLIC ACID; HEMATOPORPHYRIN; HEMATOPORPHYRIN DERIVATIVE; LUTETIUM TEXAPHYRIN; MONOCLONAL ANTIBODY; NANOPARTICLE; OXALIPLATIN; PADOPORFIN; PEPTIDE; PHEOPHORBIDE; PHOTOCHLOR; PHOTOFRIN; PHOTOLON; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PHTHALOCYANINE ZINC; PORPHOBILINOGEN DEAMINASE; PORPHYRIN; PROTEIN; PROTOPORPHYRIN; TAMOXIFEN; TEMOPORFIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VERTEPORFIN;

ACTINIC KERATOSIS; BLADDER CANCER; CARDIOVASCULAR SYSTEM TUMOR; COLORECTAL CANCER; DRUG STRUCTURE; DRUG TARGETING; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; INFLAMMATORY DISEASE; LUNG CANCER; LYMPHOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PERITONEUM CANCER; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTOXICITY; PROSTATE CANCER; REVIEW; SKIN CANCER; SKIN PHOTOTOXICITY; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 84861675931     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617830     Document Type: Review

References (195)

1. Brown, S.B.; Brown, E.A.; Walker, I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol., 2004, 5, 497-508.
2. Dougherty, T.J.; Gomer, C.J.; Henderson, B.W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic Therapy. J. Natl. Cancer Inst., 1998, 90, 889-905.
3. Nyman, E.S.; Hynninen, P.H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B: Biol., 2004, 73, 1-28.
4. Sternberg, E.D.; Dolphin, D; Bruckner, C. Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron, 1998, 54, 4151-4202.
5. Shanmugathasan, S.; Edwards, C.; Boyle, R.W. Advances in Modern Synthetic Porphyrin Chemistry. Tetrahedron, 2000, 56, 1025-1046.
6. Juillerat-Jeanneret, L. Drug targeting in cancer: photosensitizers in photodynamic therapy. Trends Cancer Res., 2006, 2, 71-84.
7. Sharman, W.M.; van Lier, J.E.; Allen, C.M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug. Deliv. Rev., 2004, 56, 53-76.
8. Lopez, R.F.; Lange, N.; Guy, R.; Bentley, M.V. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv. Drug. Deliv. Rev., 2004, 56, 77-94.
9. Agarwal, M.L.; Clay, M.E.; Harvey, E.J.; Evans, H.H.; Antunez, A.R.; Oleinick, N.L. Photodynamic Therapy Induces Rapid Cell Death by Apoptosis in L5178Y Mouse Lymphoma Cells. Cancer Res., 1991, 51, 5993-5996.
10. Foote, C.S. Definition of Type I and Type II Photosensitized Oxidation. Photochem. Photobiol., 1991, 54, 659.
11. Hsi, R.A.; Rosenthal, D.I.; Glatstein, E. Photodynamic therapy in the treatment of cancer: current state of the art. Drugs, 1999, 57, 725-734.
12. Oleinick, N.L.; Evans, H.H. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat. Res., 1998, 150, S146-S156.
13. Barberi-Heyob, M.; Vedrine, P.O.; Merlin, J.L.; Millon, R.; Abecassis, J.; Poupon, M.F.; Guillemin, F. Wild-type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis. Int. J. Oncol., 2004, 24, 951-958.
14. Allison, R.R.; Sibata, C.H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 2010, 7, 61-75.
15. O'Connor, A.E.; Gallagher, W.H.; Byrne, A.T. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem. Photobiol. 2009, 85, 1053-1074.
16. Peng, Q.; Warloe, T.; Berg, K.; Moan, J.; Kongshaug, M.; Giercksky, K.E.; Nesland, J.M. 5-Aminolevulinic acid-based photodynamic therapy. Cancer, 1997, 79, 2282-2308.
17. Kennedy, J.C.; Pottier, R.H.; Pross, D.C. Photodynamic therapy with endogenous Protoporphyrin IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B: Biol., 1990, 6, 143-148.
18. Kloek, J.; Akkermans, W.; Beijersbergen van Henegouwen, G.M. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem. Photobiol., 1998, 67, 150-154.
19. Peng, Q.; Warloe, T.; Moan, J.; Heyerdahl, H.; Steen, H.B.; Nesland, J.M.; Giercksky, K.E. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem. Photobiol., 1995, 62, 906-913.
20. Malik, Z.; Kostenich, G.; Roitman, L.; Ehrenberg, B.; Orenstein, A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J. Photochem. Photobiol. B: Biol., 1995, 28, 213-218.
21. Fukuda, H.; Paredes, S.; Battle, A.M. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp. Biochem. Physiol. B., 1992, 102, 433-436.
22. Uehlinger, P.; Zellweger, M.; Wagnieres, G.; Juillerat-Jeanneret, L.; van den Bergh, H.; Lange, N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B: Biol., 2000, 54, 72-80.
23. Berger, Y.; Greppi, A.; Siri, O.; Neier, R.; Juillerat-Jeanneret, L. Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells. J. Med. Chem., 2000, 43, 4738-4746.
24. Berger, Y.; Ingrassia, L.; Neier, R.; Juillerat-Jeanneret, L. Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg. Med. Chem., 2003, 11, 1343-1351.
25. Kloek, J.; Beijersbergen van Henegouwen, J.M.J. of 5-aminolevulinic acid for photodynamic therapy. Photochem. Photobiol., 1996, 64, 994-1000.
26. Vallinayagam, R.; Schmitt, F.; Barge, J.; Wagnières, G.; Wenger, V.; Neier, R.; Juillerat-Jeanneret, L. Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer. Bioconjug. Chem., 2008, 19, 821-839.
27. Gurba, P.; Vallinayagam, R.; Schmitt, F.; Furrer, J.; Juillerat-Jeanneret, L.; Neier, R. Novel Bioconjugates of Aminolevulinic Acid with Nucleosides. Synthesis, 2008, 24, 3957-3962.
28. Battah, S.H.; Chee, C.E.; Nakanishi, H.; Gerscher, S.; MacRobert, A.J.; Edwards, C. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjug. Chem. 2001, 12, 980-988.
29. Hilgenbrink, A.R.; Low, P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci., 2005, 94, 2135-2146.
30. Weitman, S.D.; Lark, R.H.; Coney, L.R.; Fort, D.W.; Frasca, V.; Zurawski, V.R.; Kamen, B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 1992, 52, 3396-3401.
31. Franklin, W.A.; Waintrub, M.; Edwards, D.; Christensen, K.; Prendegrast, P.; Woods, J.; Bunn, P.A.; Kolhouse, J.F. New antilung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int. J. Cancer Suppl., 1994, 8, 89-95.
32. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer, 1997, 74, 193-198.
33. Juillerat-Jeanneret, L.; Schmitt, F. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the Grail. Med. Res. Rev., 2007, 4, 574-590.
34. Schneider, R.; Schmitt, F.; Frochot, C.; Fort, Y.; Lourette, N.; Guillemin, F.; Muller, J.F.; Barberi-Heyob, M. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg. Med. Chem., 2005, 13, 2799-2808.
35. Gravier, J.; Schneider, R.; Frochot, C.; Bastogne, T.; Schmitt, F.; Didelon, J.; Guillemin, F.; Barberi-Heyob M. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies. J. Med. Chem., 2008, 51, 3867-3877.
36. Qualls, M.M.; Thompson, D.H. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity. Int. J. Cancer, 2001, 93, 384-392.
37. Stevens, P.J.; Sekido, M.; Lee, R.J. Synthesis and Evaluation of a Hematoporphyrin Derivative in a Folate Receptor-Targeted Solid-Lipid Nanoparticle Formulation. Anticancer Res., 2004, 24, 161-165.
38. Zheng, G.; Chen, J.; Li, H.; Glickson, J.D. Rerouting Conjugated Lipoproteins to Selected Alternate Receptors: A Biocompatible Nanoplatform for Delivery of Diverse Diagnostic and Therapeutic Agents. Proc. Natl. Acad. Sci. USA, 2005, 49, 17757-17762.
39. Stefflova, K.; Chen, J.; Marotta, D.; Li, H.; Zheng, G. Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ. J. Med. Chem., 2006, 49, 3850-3856.
40. Stefflova, K.; Li, H.; Chen, J.; Zheng, G. Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. Bioconjug. Chem., 2007, 18, 379-388.
41. Gotteland, M.; May, E.; May-Levin, F.; Contesso, G.; Delarue, J.C.; Mouriesse, H. Estrogen receptors (ER) in human breast cancer: the significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer, 1994, 74, 864-887.
42. Traish, A.M.; Newton, A.W.; Styperek, K.; Beazley, R.; Kavanah, M. Estrogen receptor functional status in human breast cancer. Diagn. Mol. Pathol., 1995, 4, 220-228.
43. El-Akra, N.; Noirot, A.; Faye, J.C.; Souchard JP. Synthesis of estradiol-pheophorbide a conjugates: evidence of nuclear targeting, DNA damage and improved photodynamic activity in human breast cancer and vascular endothelial cells. Photochem. Photobiol. Sci., 2006, 11, 996-999.
44. Fernandez-Gacio, A.; Fernandez-Marcos, C.; Swamy, N.; Dunn, D.; Ray R. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate. J. Cell. Biochem., 2006, 3, 665-670.
45. Swamy, N.; Purohit, A.; Fernandez-Gacio A.; Jones, G.B.; Ray R. Nuclear estrogen receptor targeted photodynamic therapy: selective uptake and killing of MCF-7 breast cancer cells by a C17α-alkynylestradiol-porphyrin conjugate. J. Cell. Biochem., 2006, 3, 966-977.
46. Khan, E.H.; Ali, H.; Tian, H.; Rousseau, J.; Tessier, G.; Shafiullah van Lier J.E. Synthesis and biological activities of phthalocyanineestradiol conjugates. Bioorg. Med. Chem. Lett., 2003, 7, 1287-1290.
47. Hakomori, S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. USA, 2002, 99, 10231-10233.
48. Smith, T.A. Facilitative glucose transporter expression in human cancer tissue. Br. J. Biomed. Sci., 1999, 56, 285-292.
49. Schell, C.; Hombrecher, H.K. Synthesis and investigation of glycosylated mono-and diarylporphyrins for photodynamic therapy. Bioorg. Med. Chem., 1999, 7, 1857-1865.
50. Laville, I.; Pigaglio, S.; Blais, J.C.; Doz F.; Loock, B.; Maillard, P.; Grierson, D.S.; Blais, J. Photodynamic efficiency of diethylene glycol-linked glycoconjugated porphyrins in human retinoblastoma cells. J. Med. Chem., 2006, 49, 2558-2567.
51. Zhang, M.; Zhang, Z.; Blessington, D.; Li, H.; Busch, T.M.; Madrak, V.; Miles, J.; Chance, B.; Glickson, J.D.; Zheng, G. Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjug. Chem., 2003, 14, 709-714.
52. Zheng, G.; Graham, A.; Shibata, M.; Missert, J.R.; Ooseroff, A.R.; Dougherty, T.J.; Pandey, R.K. Synthesis of beta-galactoseconjugated chlorins derived by enyne metathesis as galectinspecific photosensitizers for photodynamic therapy. J. Org. Chem., 2001, 66, 8709-8716.
53. Chen, X.; Hui, L.; Foster, D.A.; Drain, C.M. Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells. Biochemistry, 2004, 43, 10918-10929.
54. Frochot, C.; Di Stasio, B.; Barberi-Heyob, M.; Carre, M.C.; Zwier, J.M.; Guillemin, F.; Viriot, M.L. New glycosylated porphyrins for PDT applications. Oftalmologia, 2003, 56, 62-66.
55. Hirohara, S.; Obata, M.; Saito, A.; Ogata, S.; Ohtsuki, C.; Higashida, S.; Ogura, S.; Okura, I.; Sugai, Y.; Mikata, Y.; Tanihara, M.; Yano, S. Cellular uptake and photocytotoxicity of glycoconjugated porphyrins in hela cells. Photochem. Photobiol., 2004, 80, 301-308.
56. Desroches, M.C.; Kasselouri, A.; Meyniel, M.; Fontaine, P.; Goldmann, M.; Prognon, P.; Maillard, P.; Rosilio, V. Incorporation of glycoconjugated porphyrin derivatives into phospholipid monolayers: a screening method for the evaluation of their interaction with a cell membrane. Langmuir, 2004, 20, 11698-11705.
57. Bautista-Sanchez, A.; Kasselouri, A.; Desroches, M.C.; Blais, J.; Maillard, P.; De Oliveira, D.M.; Tedesco, A.C.; Prognon, P.; Delaire, J. Photophysical properties of glucoconjugated chlorins and porphyrins and their associations with cyclodextrins. J. Photochem. Photobiol. B: Biol., 2005, 81, 154-162.
58. Franklin, R.A.; Libra, M.; Stivala, F.; McCubrey, J.A. Two targets are better than one. Promising combination therapy to treat breast cancer. Cancer Biol. Ther., 2005, 4, 1190-1191.
59. Stein, J.A.; Brownell, I. Treatment approaches for advanced cutaneous melanoma. J. Drugs Dermatol., 2008, 7, 175-179.
60. Pepper, D.J.; Meintjes, G.A.; McIlleron, H.; Wilkinson, R.J. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discov. Today, 2007, 12, 980-989.
61. Lorigan, P.; Eisen, T.; Hauschild, A. Systemic therapy for metastatic malignant melanoma-from deeply disappointing to bright future Exp. Dermatol., 2008, 17, 383-394.
62. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nature Rev. Drug Discov., 2006, 5, 219-234.
63. Duska, L.R.; Hamblin, M.R.; Miller, J.L.; Hasan, T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J. Natl. Can. Inst., 1999, 91, 1557-1563.
64. Lottner, C.; Bart, K.C.; Bernhardt, G.; Brunner, H. Hematoporphyrin derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. J. Med. Chem., 2002, 45, 2064-2078.
65. Lottner, C.; Bart, K.C.; Bernhardt, G.; Brunner, H. Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents. J. Med. Chem., 2002, 45, 2079-2089.
66. Kim, Y.S.; Song, R.; Kim, D.H.; Jun, M.J.; Sohn, Y.S. Synthesis, biodistribution and antitumor activity of hematoporphyrinplatinum(II) conjugates. Bioorg. Med. Chem., 2003, 11, 1753-1760.
67. Lottner, C.; Knuechel, R.; Bernhardt, G.; Brunner, H. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. Cancer Lett., 2004, 203, 171-180.
68. Lottner, C.; Knuechel, R.; Bernhardt, G.; Brunner, H. Distribution and subcellular localization of a water-soluble hematoporphyrinplatinum(II) complex in human bladder cancer cells. Cancer Lett., 2004, 215, 167-177.
69. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-2466.
70. Hannon, M.J. Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl. Chem., 2007, 79, 2243-2261.
71. Jaouen, G. (ed) Bioorganometallics. 2006, Wiley-VCH, Weinheim.
72. Ang, W.H.; Dyson, P.J. Classical and non-classical rutheniumbased anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 4003-4018.
73. Melchart, M.; Sadler, P.J. in: Jaouen, G. (ed) Bioorganometallics. 2006, Wiley-VCH, Weinheim pp 50-61.
74. Ravanat, J.L.; Cadet, J.; Araki, K.; Toma, H.E.; Medeiros, M.H.G.; Di Mascio, P. Supramolecular cationic tetraruthenated porphyrin and light-induced decomposition of 2'-deoxyguanosine predominantly via a singlet oxygen-mediated mechanism. Photochem. Photobiol., 1998, 68, 698-702.
75. Süss-Fink, G. Arene ruthenium complexes as anticancer agents. Dalton Trans., 2010, 39, 1673-1688.
76. Schmitt, F.; Govindaswamy, P.; Suss-Fink, G.; Ang, W.H.; Dyson, P.J.; Juillerat-Jeanneret, L.; Therrien, B. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J. Med. Chem., 2008, 51, 1811-1816.
77. Schmitt, F.; Govindaswamy, P.; Zava, O.; Suss-Fink, G.; Juillerat-Jeanneret, L.; Therrien, B. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J. Biol. Inorg. Chem., 2009, 14, 101-109.
78. Rani-Beeram, S.; Meyer, K.; MacCrate, A.; Hong, Y.; Nielsen, M.; Swavey, S. A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: synthesis, characterization, dna binding, and melanoma cell studies. Inorg. Chem., 2008, 47, 11278-11283.
79. Gianferrara, T.; Bergamo, A.; Bratsos, I.; Milani, B.; Spagnul, C.; Sava, G.; Alessio, E. Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J. Med. Chem., 2010, 53, 4678-4690.
80. Schmitt, F.; Auzias, M.; Stepnicka, P.; Sei, Y.; Yamaguchi, K.; Suss-Fink, G.; Therrien, B.; Juillerat-Jeanneret L. Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells. J. Biol. Inorg. Chem., 2009, 14, 693-701.
81. Obata, M.; Hirohara, S.; Tanaka, R.; Kinoshita, I.; Ohkubo, K.; Fukuzumi, S.; Tanihara, M.; Yano, S. In vitro heavy-atom effect of palladium(II) and platinum(II) complexes of pyrrolidine-fused chlorin in photodynamic therapy. J. Med. Chem., 2009, 52, 2747-2753.
82. Maziere, J.C.; Morliere, P.; Santus R. The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. J. Photochem. Photobiol. B: Biol., 1991, 4, 351-360.
83. Niamien Konan, Y.; Gurny, E.; Allemann, E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B: Biol., 2002, 66, 89-106.
84. Vitols S. Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications. Cancer Cells, 1991, 12, 488-495.
85. Hamblin, M.R.; Newman E.L. Photosensitizer targeting in photodynamic therapy II. Conjugates of haematoporphyrin with serum lipoproteins. J. Photochem. Photobiol., 1994, 26, 147-157.
86. Polo, L.; Valduga, G.; Jori, G.; Reddi, E. Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int. J. Biochem. Cell. Biol., 2002, 34, 10-23.
87. Schmidt-Erfurth, U.; Diddens, H.; Birngruber, R.; Hasan, T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br. J. Cancer, 1997, 75, 54-61.
88. Reddi, E. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. J. Photochem. Photobiol. B: Biol., 1997, 37, 189-195.
89. Jori, G.; Reddi, E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int. J. Biochem., 1993, 25, 1369-1375.
90. Zhou, C.; Milanesi, C.; Jori, G. An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins. Photochem. Photobiol., 1988, 48, 487-492.
91. Lees, A.M.; Lees, R.S. 99mTechnetium-labeled low density lipoprotein: receptor recognition and intracellular sequestration of radiolabel. J. Lipid. Res., 1991, 32, 1-8.
92. Li, H.; Zhang, Z.; Blessington, D.; Nelson, D.S.; Zhou, R.; Lund-Katz, S.; Chance, B.; Glickson, J.D.; Zheng, G. Carbocyanine labeled LDL for optical imaging of tumors. Acad. Radiol., 2004, 6, 669-677.
93. Corbin, I.R.; Li, H.; Chen, J.; Lund-Katz, S.; Zhou, R.; Glickson, J.D.; Zheng, G. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia, 2006, 8, 488-498.
94. Song, L.; Li, H.; Sunar, U.; Chen, J.; Corbin, I.; Yodh, A.G.; Zheng, G. Naphthlocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int. J. Nanomed., 2007, 2, 767-774.
95. Cao, W.; Ng, K.K.; Corbin, I.; Zhang, Z.; Ding, L.; Chen, J.; Zheng, G. Synthesis and evaluation of a stable bacteriochlorophyllanalog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug. Chem. 2009, 20, 2023-2031.
96. Salomon, D.S.; Brandt R.; Ciardiellob, F.; Normannoc, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19, 183-232.
97. Lutsenko, S.V.; Feldman, N.B.; Finakova, G.V.; Posypanova, G.A.; Severin, S.E.; Skryabin, K.G.; Kirpichnikov, M.P.; Lukyanets, E.A.; Vorozhtsov, G.N. Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates. Tumor Biol., 1999, 20, 218-224.
98. Gijsens A.; Missiaen, L.; Merlevede, W.; De Witte, P. Epidermal Growth Factor-mediated Targeting of Chlorin e6 Selectively Potentiates Its Photodynamic Activity. Cancer Res., 2000, 60, 2197-2202.
99. Savellano, P.; Hasan, T. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin. Can. Res., 2005, 11, 1658-1668.
100. Kuo, W.S.; Chang, C.N.; Chang, Y.T.; Yang, M.H.; Chien, Y.H.; Chen, S.J.; Yeh, C.S. Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew. Chem. Int. Ed. 2010, 49, 2711-5.
101. Testa, U.; Pelosi, E.; Peschle C. The transferrin receptor. Crit. Rev. Oncog., 1993, 4, 241-276.
102. Hamblin, M.R.; Newman E.L. Photosensitizer targeting in photodynamic therapy I. Conjugates of haematoporphyrin with albumin and transferrin. J. Photochem. Photobiol. B: Biol., 1994, 26, 45-56.
103. Laptev, R.; Nisnevitch, M.; Siboni, G.; Malik, Z.; Firer, M.A. Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells. Br. J. Cancer, 2006, 95, 189-196.
104. Cavanaugh, P.G. Synthesis of Chlorin e6-Transferrin and Demonstration of Its Light-Dependent in vitro Breast Cancer Cell Killing Ability. Breast Cancer Res. Treat., 2002, 72, 117-130.
105. Gijsens, A.; Derycke, A.S.; Missiaen, L.; De Vos, D.; Huwyler, J.; Eberle, A.; De Witte, P.A. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEGliposomes. Int. J. Cancer, 2002, 101, 78-85.
106. Derycke, A.S.; Kamuhabwa, A.; Gijsens, A.; Roskams, T.; De Vos, D.; Kasran, A.; Huwyler, J.; Missiaen, L.; De Witte, P.A. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J. Natl. Cancer Inst., 2004, 96, 1620-1630.
107. Akhlynina, T.V.; Rosenkranz, A.A.; Jans, D.A.; Sobolev, A.S. Insulin-mediated intracellular targeting enhances the photodynamic activity. Cancer Res. 1995, 55, 1014-1019.
108. Van Dongen, G.A.; Visser, G.W.; Vrouenraets, M.B. Photosensitizerantibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev., 2004, 56, 31-52.
109. De Bono, J.S.; Rowinsky E.K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med., 2002, 8, S18-S26.
110. Savellano, M.D.; Pogue, B.W.; Hoopes, P.J.; Vitetta, E.S.; Paulsen, K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res., 2005, 65, 6371-6379.
111. Bhatti, M.; Yahioglu, G.; Milgrom, L.R.; Garcia-Maya, M.; Chester, K.A.; Deonarain, M.P. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer, 2008, 122, 1155-1163.
112. Mayo, G.L.; Melendez, R.F.; Kumar, N.; McKinnon, S.J.; Glickman, R.D. Antibody-targeted photodynamic therapy. Am. J. Ophtalmol., 2003, 136, 1151-1152.
113. Novichenko, N.L.; Mamchur, A.A.; Lisniak, I.O.; Gamaliya, M.F. Study of photodynamic efficiency of the hematoporphyrin conjugated with antibody to VEGF in mouse Lewis carcinoma. Exp. Oncol., 2008, 30, 315-318.
114. Castellani, P.; Viale, G.; Dorcaratto, A.; Nicolo, G.; Kaczmarek, J.; Querze, G.; Zardi, L. The fibronectin isoform containing ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer, 1994, 59, 612-618.
115. Fabbrini, M.; Trachsel, E.; Soldani, P.; Bindi, S.; Alessi, P.; Bracci, L.; Kosmehl, H.; Zardi, L.; Neri, D.; Neri, P. Selective occlusion of tumour blood vessels by targeted delivery of an antibodyphotosensitizer conjugate. Int. J. Cancer, 2006, 118, 1805-1813.
116. Vrouenraets, M.B.; Visser, G.W.; Loup, C.; Meunier, B.; Stigter, M.; Oppelaar, H.; Stewart, F.A.; Snow, G.B.; Van Dongen, G.A. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int. J. Cancer, 2000, 88, 108-114.
117. Vrouenraets, M.B.; Visser, G.W.; Stigter, M.; Oppelaar, H.; Stewart, F.A.; Snow, G.B.; Van Dongen, G.A. Targeting of Aluminum (III) Phthalocyanine Tetrasulfonate by Use of Internalizing Monoclonal Antibodies: Improved Efficacy in Photodynamic Therapy. Cancer Res., 2001, 61, 1970-1975.
118. Staneloudi, C.; Smith, K.A.; Hudson, R.; Malatesti, N.; Savoie, H.; Boyle, R.W.; Greenman, J. Development and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer. Immunology, 2007, 120, 512-517.
119. Del Governatore, M.; Hamblin, M.; Shea, C.R.; Rizvi, I.; Molpus, K.G.; Tanabe, K.K.; Hasan, T. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res., 2000, 60, 4200-4205.
120. Duan, W.; Smith, K.; Savoie, H.; Greenman, J.; Boyle, R.W. Near IR emitting isothiocyanato-substituted fluorophores: their synthesis and bioconjugation to monoclonal antibodies. Org. Biomol. Chem., 2005, 3, 2384-2386.
121. Bergstrom, L.C.; Vucenik, I.; Hagen, I.K.; Chernomorsky, S.A.; Poretz, R.D. In-vitro photocytotoxicity of lysosomotropic immunoliposomes containing pheophorbide a with human bladder carcinoma cells. J. Photochem. Photobiol. B: Biol., 1994, 24, 17-23.
122. Morgan, J.; MacRobert, A.J.; Gray, A.G.; Huenhs, E.R. Use of photosensitive, antibody directed liposomes to destroy target populations of cells in bone marrow: a potential purging method for autologous bone marrow transplantation. Br. J. Cancer, 1992, 65, 58-64.
123. Adessi, C.; Soto, C. a peptide into a drug: Strategies to improve stability and bioavailability. Curr. Med. Chem., 2002, 9, 963-978.
124. Schneider, R.; Tirand, L.; Frochot, C.; Vanderesse, R.; Thomas, N.; Gravier, J.; Guillemin, F.; Barberi-Heyob, M. Recent improvements in the use of synthetic peptides for selective photodynamic therapy. Curr. Med. Chem. Anti-Cancer Agents, 2006, 6, 469-488.
125. Spikes, J.D.; Bommer, J.C. Photosensitizing properties of mono-Laspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors. J. Photochem. Photobiol. B: Biol., 1993, 17, 135-143.
126. Kennedy, J.C.; Nadeau, P.; Petryka, Z.J.; Pottier, R.H.; Weagle, G. Clearance times of porphyrin derivatives from mice as measured by in vivo fluorescence spectroscopy. Photochem. Photobiol., 1992, 55, 729-734.
127. Anonymous. Talaporfin: LS 11, LS11, ME 2906, Mono-L-Aspartyl Chlorin e6, NP e6, NPE 6, Taporfin Sodium. Drugs in R & D, 2003, 4, 69-71.
128. Wang, H.M.; Jiang, J.Q.; Xiao, J.H.; Gao, R.L.; Lin, F.Y.; Liu, X.Y. Porphyrin with amino acid moieties: a tumor photosensitizer. Chem. Biol. Interac., 2008, 172, 154-158.
129. Graczyk, A.; Kwasny, M.; Ye, S.; Milosz, E.; Kowalska, A.; Podhajska, A. Diaminoacid derivatives of protoporphyrine used as photosensitizers in photodynamic method of tumor diagnosis and treatment. Proc. SPIE, 2003, 5229, 91-96.
130. Kwitniewski, M.; Jezeniene, A.; Ma, L.W.; Glosnicka, R.; Graczyk, A.; Moan, J. Diamino acid derivatives of PpIX as potential photosensitizers for photodynamic therapy of squamous cell carcinoma and prostate cancer: In vitro studies. J. Photochem. Photobiol. B. Biol., 2009, 94, 214-222.
131. Drechsler, U.; Pfaff, M.; Hanack, M. Synthesis of Novel Functionalised Zinc Phthalocyanines Applicable in Photodynamic Therapy. Eur. J. Org. Chem., 1999, 3441-3453.
132. Taquet, J. P.; Frochot, C.; Manneville, V.; Barberi-Heyob, M. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy. Curr. Med. Chem., 2007, 14, 1673-1687.
133. Bugaj, A.; Morliere, P.; Santus, R.; Haigle, J.; Dyderski, S. Phototoxicity of protoporphyrin IX, diarginine diprotoporphyrinate and N, N-diphenylalanyl protoporphyrin toward human fibroblasts and keratinocytes in vitro: effect of 5-methoxypsoralen. Photochem. Photobiol., 2004, 80, 486-491.
134. Tsay, J.M.; Trzoss, M.; Shi, L.; Kong, X.; Selke, M.; Jung, M.E.; Weiss, S. Singlet oxygen production by peptide-coated quantum dot-photosensitizer conjugates. J. Am. Chem. Soc., 2007, 129, 6865-6871.
135. El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of Macromolecules using Arginine-rich Cell Penetrating Peptides: Ways to Overcome Endosomal Entrapment. AAPS J., 2009, 11, 13-22.
136. Choi, Y.; MacCarthy, J.R.; Weissleder, R.; Tung, C.H. Conjugation of a photosensitizer to an oligoarginine-based cell-penetrating peptide increases the efficacy of photodynamic therapy. ChemMedChem., 2006, 1, 458-463.
137. Dixon, M.J.; Bourre, L.; MacRobert, A.J.; Eggleston, I.M. Novel prodrug approach to photodynamic therapy: Fmoc solid-phase synthesis of a cell permeable peptide incorporating 5-aminolaevulinic acid. Bioorg. Med. Chem. Let., 2007, 17, 4518-4522.
138. Soukos, N.S.; Hamblin, M.R.; Hasan, T. The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates. Photochem. Photobiol., 1997, 65, 723-729.
139. Hamblin, M.R.; Rajadhyaksha, M.; Momma, T.; Soukos, N.S.; Hasan, T. In vivo fluorescence imaging of the transport of charged chlorine6 conjugates in a rat orthotopic prostate tumour. Br. J. Cancer, 1999, 81, 261-268.
140. Hamblin, M.R.; Miller, J.L.; Rizvi, I.; Ortel, B.; Maytin, E.V.; Hasan, T. Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res., 2001, 61, 7155-7162.
141. Sibrian-Vazquez, M.; Jensen, T.J.; Vicente, M.G.H. Synthesis, characterization, and metabolic stability of porphyrin-peptide conjugates bearing bifunctional signaling sequences. J. Med. Chem., 2008, 51, 2915-2923.
142. Sehgal, I.; Sibrian-Vazquez, M.; Vicente, M.G.H. Photo-induced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins. J. Med. Chem., 2008, 51, 6014-6020.
143. Sibrian-Vazquez, M.; Jensen, T.J.; Vicente, M.G.H. Influence of the number and distribution of NLS peptides on the photosensitizing activity of multimeric porphyrin-NLS. Org. Biomol. Chem., 2010, 8, 1160-1172.
144. Rosenkranz, A. A; Jans, D.A.; Sobolev, A.S. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol. Cell Biol., 2000, 78, 452-464.
145. Chaloin, L.; Bigey, P.; Loup, C.; Marin, M.; Galeotti, N.; Piechaczyk, M.; Heitz, F.; Meunier, B. Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide. Bioconjugate Chem., 2001, 12, 691-700.
146. Walker, I.; Vernon, D.I.; Brown, S.B. The solid-phase conjugation of purpurin-18 with a synthetic targeting peptide. Bioorg. Med. Chem. Lett., 2004, 14, 441-443.
147. Dozzo, P.; Koo, M.S.; Berger, S.; Forte, T.M.; Kahl, S.B. Synthesis, characterization, and plasma lipoprotein association of a nucleus-targeted boronated porphyrin. J. Med. Chem., 2005, 48, 357-359.
148. Morgan, J.; Oseroff, A.R. Mitochondria-based photodynamic anticancer therapy. Adv. Drug Del. Rev., 2001, 49, 71-86.
149. Sibrian-Vazquez, M.; Nesterova, I.V.; Jensen, T.J.; Vicente, M.G.H. Mitochondria-targeting by guanidine-and biguanidine-porphyrin photosensitizers. Bioconjugate Chem., 2008, 19, 705-713.
150. Lovell, J.F.; Chen, J.; Jarvi, M.T.; Cao, W.G.; Allen, A.D.; Liu, Y.; Tidwell, T.T.; Wilson, B.C.; Zheng, G. FRET Quenching of Photosensitizer Singlet Oxygen Generation. J. Phys. Chem. B, 2009, 113, 3203-3211.
151. Chen, J.; Jarvi, M.; Lo, P.C.; Stefflova, K.; Wilson, B.C.; Zheng, G. Using the singlet oxygen scavenging property of carotenoid in photodynamic molecular beacons to minimize photodamage to non-targeted cells. Photochem. Photobiol. Sci., 2007, 6, 1311-1317.
152. Zheng, G.; Chen, J.; Stefflova, K.; Jarvi, M.; Li, H.; Wilson, B.C. Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc. Natl. Acad. Sci. USA, 2007, 104, 8989-8994.
153. Chen, J.; Liu, T.W.B.; Lo, P.C.; Wilson, B.C.; Zheng, G. Zipper molecular beacons: a generalized strategy to optimize the performance of activable protease probes. Bioconjug. Chem. 2009, 20, 1836-1842.
154. Scanlan, M.J.; Mohan Raj, B.K.; Calvo, B.; Garin-Chesa, P.; Sanz-Moncasi, P.; Healey, J.H.; Old, L.J.; Rettig, W.J. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA, 1994, 91, 5657-5661.
155. Lo, P.C.; Chen, J.; Stefflova, K.; Warren, M.S.; Navab, R.; Bandarchi, B.; Mullins, S.; Tsao, M.; Cheng, J.D.; Zheng, G. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J. Med. Chem., 2009, 52, 358-368.
156. Choi, Y.; Weissleder, R.; Tung, C.H. Protease-mediated phototoxicity of a polylysine-chlorine6 conjugate. ChemMedChem, 2006, 1, 698-701.
157. Choi, Y.; Weissleder, R.; Tung, C.H. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res., 2006, 66, 7225-7229.
158. Campo, M.A.; Gabriel, D.; Kucera, P.; Gurny, R.; Lange, N. Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem. Photobiol., 2007, 83, 958-965.
159. Gabriel, D.; Campo, M.A.; Gurny, R.; Lange, N. Tailoring protease-sensitive photodynamic agents to specific diseaseassociated enzymes. Bioconjug. Chem., 2007, 18, 1070-1077.
160. Gabriel, D.; Busso, N.; So, A.; van der Bergh, H.; Gurny, R.; Lange, N. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. J. Control. Rel., 2009, 138, 225-234.
161. Casas, A.; Batlle, A.M.; Butler, A.R.; Robertson, D.; Brown, E.H.; MacRobert, A.; Riley, P.A. Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br. J. Cancer, 1999, 80, 1525-1535.
162. Juillerat-Jeanneret, L.; Lohm, S.; Hamou, M.F.; Pinet, F. Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta. Lab. Invest., 2000, 80, 973-980.
163. Berger, Y.; Chapuis-Bernasconi, C.; Schmitt, F.; Neier, R.; Juillerat-Jeanneret, L. Determination of intracellular prolyl/glycylspecific proteases in intact living human cells using protoporphyrin IX production as a reporter system. Chem. Biol., 2005, 12, 867-872.
164. Rogers, L.M.A.; MacGivern, P.G.; Butler, A.R.; MacRobert, A.J.; Eggleston, I.M. An efficient synthesis of 5-aminolaevulinic acid (ALA)-containing peptides for use in photodynamic therapy. Tetrahedron, 2005, 61, 6951-6958.
165. Bourre, L.; Giuntini, F.; Eggleston, I.M.; Wilson, M.; MacRobert, A.J. 5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy. Mol. Cancer Ther., 2008, 7, 1720-1729.
166. Giuntini, F.; Bourre, L.; MacRobert, A.J.; Wilson, M.; Eggleston, I.M. Improved peptide prodrugs of 5-ALA for PDT: rationalization of cellular accumulation and protoporphyrin IX production by direct determination of cellular prodrug uptake and prodrug metabolization. J. Med. Chem., 2009, 52, 4026-4037.
167. Chen, B.; Pogue, B.W.; Hoopes, P.J.; Hasan, T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukar. Gene Expression, 2006, 16, 279-305.
168. Medina, M. A.; Munoz-Ch Puli, R.; Quesada, A. R. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J. Cell. Mol. Med., 2007, 11, 374-382.
169. 3 for angiogenesis. Science, 1994, 264, 569-571.
170. Dunehoo, A.L.; Anderson, M.; Majumdar, S.; Kobayashi, N.; Berkland, C.; Siahaan, T.J. Cell adhesion molecules for targeted drug delivery. J. Pharm. Sci., 2006, 95, 1856-1872.
171. Chaleix, V.; Sol, V.; Huang, Y.M.; Guilloton, M.; Granet, R.; Blais, J.C.; Krausz, P. RGD-porphyrin conjugates: Synthesis and potential application in photodynamic therapy. Eur. J. Org. Chem., 2003, 1486-1493.
172. Chaleix, V.; Sol, V.; Guilloton, M.; Granet, R.; Krausz, P. Efficient synthesis of RGD containing cyclic peptide-porphyrin conjugates by ring-closing metathesis on solid support. Tetrahedron Lett., 2004, 45, 5295-5299.
173. Frochot, C.; Di Stasio, B.; Vanderesse, R.; Belgy, M.J.; Dodeller, M.; Guillemin, F.; Viriot, M.L.; Barberi-Heyob, M. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg. Chem., 2007, 35, 205-220.
174. Conway, C.L.; Walker, I.; Bell, A.; Roberts, D.J.H.; Brown, S.B.; Vernon, D.I. In vivo and in vitro characterization of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy. Photochem. Photobiol. Sci., 2008, 7, 290-298.
175. Ferrara, N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocr. Rev., 2004, 25, 581-611.
176. Soker, S.; Takashima, S.; Miao, H.Q.; Neufeld, G.; Klagsburn, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 1998, 92, 735-745.
177. Tirand, L.; Frochot, C.; Vanderesse, R.; Thomas, N.; Trinquet, E.; Pinel, S.; Viriot, M.L.; Guillemin, F.; Barberi-Heyob, M. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J. Control. Rel., 2006, 111, 153-164.
178. Renno, R.Z.; Terada, Y.; Haddadin, M.J.; Michaud, N.A.; Gragoudas, E.S.; Miller, J.W. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophtalmol., 2004, 122, 1002-1011.
179. Tirand, L.; Thomas, N.; Dodeller, M.; Dumas, D.; Frochot, C.; Maunit, B.; Guillemin, F.; Barberi-Heyob, M. Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study. Drug Metab. Dispos., 2007, 35, 806-813.
180. Thomas, N.; Bechet, D.; Becuwe, P.; Tirand, L.; Vanderesse, R.; Frochot, C.; Guillemin, F.; Barberi-Heyob, M. Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo. J. Photochem. Photobiol. B: Biol., 2009, 96, 101-108.
181. Bechet, D.; Tirand, L.; Faivre, B.; Plenat, F.; Bonnet, C.; Bastogne, T.; Frochot, C.; Guillemin, F.; Barberi-Heyob, M. Neuropilin-1 Targeting Photosensitization-Induced Early Stages of Thrombosis via Tissue Factor Release. Pharm. Res., 2009, 27, 468-479.
182. Thomas, N.; Pernot, M.; Vanderesse, R.; Becuwe, P.; Kamarulzaman, E.; Da Silva, D.; Francois, A.; Frochot, C.; Guillemin, F.; Barberi-Heyob, M. Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties. Biochem. Pharmacol., 2010, 226-35.
183. Tang, Y.; Borgstrom, P.; Maynard, J.; Koziol, J.; Hu, Z.; Garen, A.; Deisseroth A. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther., 2007, 14, 346-353.
184. Hu, Z.; Rao, B.; Chen, S.; Duanmu, J. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer, 2010, 10, 235-247.
185. Bechet, D.; Couleaud, P.; Frochot, C.; Viriot, M.L.; Guillemin, F.; Barberi-Heyob, M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotech., 2008, 26, 612-621.
186. Kopelman, R.; Koo, Y.E.L.; Philbert, M.; Moffat, B.A.; Reddy, G.R.; MacConville, P.; Hall, D.H.; Chenevert, T.L.; Bhojani, M.S.; Buck, S.M.; Rehemtulla, A.; Ross, B.D. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. J. Magn. Magn. Mat., 2005, 293, 404-410.
187. Ruoslahti, E.; Duza, T.; Zhang, L. Vascular homing peptides with cell-penetrating properties. Curr. Pharm. Des., 2005, 11, 3655-3660.
188. Reddy, G.R.; Bhojani, M.S.; MacConville, P.; Moody, J.; Moffat, B.A.; Hall, D.E.; Kim, G.; Koo; Y.E.L.; Woolliscroft, M.J.; Sugai, J.V.; Johnson, T.D.; Philbert, M.A.; Kopelman, R.; Rehemtulla, A.; Ross, B.D. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res., 2006, 12, 6677-6686.
189. Ichikawa, K.; Hikita, T.; Maeda, N.; Yonezawa, S.; Takeuchi, Y.; Asai, T.; Namba, Y.; Oku, N. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta, 2005, 1669, 69-74.
190. Shukla, R.; Thomas, T.P.; Peters, J.; Baker, J.R. Jr. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem. Commun., 2005, 46, 5739-5741.
191. Delehanty, J.B.; Medintz, I.L.; Pons, T.; Brunel, F.M.; Dawson. P.E.; Mattoussi, H. Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery. Bioconj. Chem., 2006, 17, 920-927.
192. Rozenzhak, S.M.; Kadakia, M.P.; Caserta, T.M.; Westbrook, T.R.; Stone, M.O.; Naik, R.R. Cellular internalization and targeting of semiconductor quantum dots. Chem. Commun., 2007, 17, 2217-2219.
193. Lieleg, O.; Lopez-Garcia, M.; Semmrich, C.; Auernheimer, J.; Kessler, H.; Bausch, A.R. Specific Integrin Labeling in Living Cells Using Functionalized Nanocrystals. Small, 2007, 3, 1560-1565.
194. Smith, B.R.; Cheng, Z.; De, A.; Koh, A.L.; Sinclair, R.; Gambhir, S.S. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 2008, 8, 2599-2606.
195. Biju, V.; Muraleedharan, D.; Nakayama, K.I.; Shinohara, Y.; Itoh, T.; Baba, Y.; Ishikawa, M. Quantum dot-insect neuropeptide conjugates for fluorescence imaging, transfection, and nucleus targeting of living cells. Langmuir, 2007, 23, 10254-10261.